Last reviewed · How we verify
biphasic human insulin 50
Biphasic human insulin 50 is a combination insulin product that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes.
Biphasic human insulin 50 is a combination insulin product that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | biphasic human insulin 50 |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | Insulin (biphasic human insulin) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This product contains 50% soluble (regular) human insulin for immediate postprandial glucose control and 50% isophane (NPH) insulin for basal coverage. The biphasic formulation mimics physiological insulin secretion patterns by delivering quick glucose-lowering action after meals combined with sustained background insulin activity throughout the day.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Influence of the Fruit Matrix on Glucose and Insulin Responses After the Intake of Orange Juice in Healthy Human Males (NA)
- Comparison of Thrice-Daily Premixed Human Insulin with Basal-Bolus Therapy Among Patients with Poorly Controlled Type 2 Diabetes Mellitus (PHASE4)
- Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus. (PHASE3)
- Premixed vs Basal Bolus Insulin Therapy in Older Patients With Type 2 Diabetes (PHASE4)
- Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes (PHASE3)
- Comparison of Two Formulations of Biphasic Insulin Aspart 70 (PHASE1)
- Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects (PHASE1)
- Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- biphasic human insulin 50 CI brief — competitive landscape report
- biphasic human insulin 50 updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI